These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34402473)

  • 21. Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis.
    Kuchay MS; Misra A
    Diabetes Metab Syndr; 2022 Mar; 16(3):102446. PubMed ID: 35259705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and Profile of Fibrosis in Diabetic Patients with Non-alcoholic Fatty Liver Disease and the Associated Factors.
    Prasetya IB; Hasan I; Wisnu W; Rumende CM
    Acta Med Indones; 2017 Apr; 49(2):91-98. PubMed ID: 28790222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
    Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
    Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Non-alcoholic fatty liver disease and type 2 diabetes mellitus: issues of the liver fibrosis diagnostics].
    Anisonyan AV; Sandler YG; Khaimenova TY; Keyan VA; Saliev KG; Sbikina ES; Vinnitskaya EV
    Ter Arkh; 2020 Sep; 92(8):73-78. PubMed ID: 33346465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes.
    Noureddin N; Noureddin M; Singh A; Alkhouri N
    Dig Dis Sci; 2022 Apr; 67(4):1379-1388. PubMed ID: 33779880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Non-Alcoholic Fatty Liver Disease].
    Brůha R
    Vnitr Lek; 2019; 65(9):571-575. PubMed ID: 31635468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility and efficiency of European guidelines for NAFLD assessment in patients with type 2 diabetes: A prospective study.
    Besutti G; Bonilauri L; Manicardi E; Venturelli F; Bonelli E; Monelli F; Manicardi V; Valenti L; Ligabue G; Schianchi S; Massari M; Riva N; Froio E; Tagliavini E; Pattacini P; Giorgi Rossi P
    Diabetes Res Clin Pract; 2021 Jul; 177():108882. PubMed ID: 34082056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia.
    Junker AE; Gluud L; Holst JJ; Knop FK; Vilsbøll T
    J Intern Med; 2016 May; 279(5):485-93. PubMed ID: 26728692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China.
    Yu X; Chen C; Guo Y; Tong Y; Zhao Y; Wu L; Sun X; Wu X; Song Z
    Ann Med; 2021 Dec; 53(1):1621-1631. PubMed ID: 34498502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.
    Duseja A; Singh SP; Mehta M; Shalimar ; Venkataraman J; Mehta V; Devadas K; Kar SK; Goyal O; Nagral A; Saigal S; Nijhawan S; Praharaj D; Shukla A; Sharma B; Narayanasamy K; Kumar P; Rao PN; Arora A; Mehta R; Asati P; Ranjan P; Koshy A; Alam S; Mukewar S; Mukewar S; Mohan Prasad VG; Rastogi M; Sanyal AJ
    Metab Syndr Relat Disord; 2022 Apr; 20(3):166-173. PubMed ID: 35085026
    [No Abstract]   [Full Text] [Related]  

  • 33. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
    Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
    Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus.
    Khneizer G; Rizvi S; Gawrieh S
    Adv Exp Med Biol; 2021; 1307():417-440. PubMed ID: 32424494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prevalence of nonalcoholic liver steatosis in patients with type 2 diabetes mellitus in the Czech Republic.
    Dvorak K; Hainer R; Petrtyl J; Zeman M; Vareka T; Zak A; Sroubkova R; Svestka T; Vitek L; Bruha R
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):442-8. PubMed ID: 25004910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts.
    Kim J; Lee M; Kim SY; Kim JH; Nam JS; Chun SW; Park SE; Kim KJ; Lee YH; Nam JY; Kang ES
    Endocrinol Metab (Seoul); 2021 Aug; 36(4):823-834. PubMed ID: 34474517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?
    Vincent RK; Williams DM; Evans M
    Diabetes Obes Metab; 2020 Dec; 22(12):2227-2240. PubMed ID: 32945071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 40. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA.
    Wijarnpreecha K; Kim D; Raymond P; Scribani M; Ahmed A
    Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1121-1128. PubMed ID: 30888971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.